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1. Introduction 
Prostate cancer is considered one of the most discussed topics in male health with an 
important social impact on the quality of life.  
In Europe, it is the most common solid neoplasm with an incidence rate of 214 cases per 
100,000 men1. The increasing life expectancy and the more and more widespread use of 
Prostate Specific Antigen (PSA) are probably the two most important reasons why more 
patients are diagnosed with prostate cancer. In Europe, 2,6 million new cases of prostate 
cancer are yearly observed (11% of male cancer diagnosis), responsible for 9% of deaths for 
male cancer cases.  
Radical surgery represents the treatment of choice in clinically localized prostate cancer and 
in > 10 year life expectancy prostate cancer. Nevertheless, radical surgery itself may be 
considered a high morbility treatment2.  
Mini-invasive procedure development, such as three-dimensional external radiotherapy, 
brachytherapy or cryotherapy, especially in elderly or anaesthetically high risk patients, 
represents a useful treatment in prostate cancer.  
HIFU (High-Intensity Focused Ultrasound) is a new and alternative choice in localized and 
low or intermediate-risk prostate cancer treatment3-5.  
For a variety of reasons, transrectal HIFU appears highly attractive as a minimally 
invasive treatment for localized prostate cancer. It is a method of delivering ultrasonic 
energy with resultant heat and tissue destruction to a discrete point without damaging 
intervening tissue or cells. HIFU has been used for the management of patients diagnosed 
with various types of cancer, including prostate, breast, liver, pancreas, kidney, bone, and 
soft tissue. 
2. Experimental studies 
It has been shown in canines and humans that HIFU is capable of ablating prostatic tissue 
both contact and irradiation free6,7. 
One of the first investigators who experimented the application of the technique to human 
beings has been S. Madersbacher8. 
Early studies considered focused ultrasound as a potential technique for neurosurgery 
(Lynn, 1942; Warwick and Pond, 1968). A significant development was the construction of 
precision apparatus suitable for human treatment by Fry et al. in 1958. 
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HIFU has also been used in other clinical fields including ophthalmology (Coleman, 1985), 
urology (by Foster and Gelet in 1993) and oncology (Chapelon in 1992 and Prat in 1995). To 
date, focused ultrasound has been used successfully in the management of many tumours, 
including prostate cancer, in which this technique represents a good treatment option. 
HIFU was also used by Madersbacher and colleagues as a treatment for Benign Prostatic 
Hyperplasia (BPH). To date, this technique is not still used to treat BPH, because of its side 
effects on bladder neck function. 
3. Description of the procedure 
HIFU is performed through a computerized surgical device equipped with a treatment 
table, an ultrasound treatment system connected to an endorectal probe, a safety infrared 
ray detector, a refrigeration system keeping the rectal mucosa temperature below 14°C and 
a monitor to set and control the treatment procedure through echographic screening (Fig. 1). 
For anatomical reasons, the transrectal approach appears ideally suited to ablate prostatic 
tissue because the proximity of HIFU transducer and target tissue facilitates HIFU treatment 
from the technical standpoint.  
After introducing the rectal probe, anatomic landmarks must be echographically set (apex, 
bladder neck, rectal side, prostate capsule), in order to make the computer able to determine 
the correct subdivision in different prostate portions (generally four).  
The probe is equipped with a transducer that gives out a beam of high-focused convergent 
ultrasounds. The HIFU transducer has an aperture of 37 cm and a focal distance of 25.5 cm.  
The focus has a -6 dB beam width of 1.6 mm and axial length of 10 mm. In the ultrasound 
converging point (focal point), the ultrasound beam absorption generates an immediate 
growth of temperature (85-100°C), destroying prostate cells in the circumscribed area. 
 
 
(Ablatherm®-Edap Technomed device). 
Fig. 1. Overview of HIFU procedure. The bed with the High-intensity ultrasound probe can 
be clearly seen. On the right, the ultrasound screen and the screen to set the machine and 
follow the procedure  
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Adequately translating the focal point with a robotic and automatic device, the successive 






Fig. 2. Anatomical scheme of HIFU endorectal device 
These lesions have a predictable size and shape, closely matching the focal region of the 
ultrasound source. As the lesion width is almost constant along their length, they can be 




             
 
Fig. 3. HIFU mechanism scheme. On the left, ultrasound beam positioning; in the middle, 
the area to treat; on the right, an overall view of the sections treated by high-intensity 
ultrasound. 
A standard procedure can be personalized in order to obtain ideal treatment settings: 
ultrasound frequency (standard 3 MHz), shot duration (standard 5 seconds) and waiting-
time between shots (standard 5 seconds) may be modified (Fig. 4). Elementary lesion 
volume measures 19-24 mm and its diameter measures 1.7 mm 
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Fig. 4. On the screen, it is possible to follow the procedure and to change settings, such as 
ultrasound frequency and shot duration. Thus, a safe and optimal treatment can be performed. 
4. Management of the patient before and after the procedure 
In order to safely perform the treatment, the surgeon is advised to follow some 
recommendations, in accordance with the European  and American guidelines: 
a. Anti-trombotic prophylaxis with sodic Dalteparin 5.000 I.U. the day before the 
procedure. Other low molecular weight heparin (LMWH) can be administrated, 
according with local policies. 
b. Antibiotic prophylaxis should be given in order to prevent infection. A quinolone 
represents a good choice, but other antibiotic can be used, according with local policies. 
c. Careful intestinal toilet. This is an important key point in infection prevention. Also, it 
is fundamental to obtain a good view of the whole prostate on ultrasound, which is 
important in order to treat the target area properly. This will also prevent some side 
effects of the treatment, such as bladder neck irritation, reduces the risk of rectum 
fistulisation, and improves the erectile function outcome. 
All patients undergo intra-spinal block with Chirocaine®.  
Marcaine® can be used instead of Chirocaine.  
If Marcaine is administrated, it is important to begin the procedure from the left lobe of the 
prostate, because this lobe is above due to the left decubitus of the patient on the device.  
In order to make the procedure more bearable and to obtain the best cooperation from the 
patient, Midazolam 0,03 mg/kg administration during the procedure is recommended. 
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Other benzodiazepine can be used, according with their pharmacocynetic and 
pharmacodynamic features. 
Reportedly, patients have no postoperative pain, except in case of complication. Just in the 
first two hours after the treatment the patient might complain of confusion and dazzling, 
but these are considered common consequences of the anaesthetic treatment.  
The anaesthetist should be involved pre-operatively, intra-operatively and post-operatively, 
in order to manage the patient properly before and during the treatment and in order to 
relieve post-operative pain and anaesthetic side-effects and/or complications. 
5. Mechanism 
Conceptually, a piezoelectric transducer generates a high intensity converging ultrasound 
beam that destroys local tissues through three mechanisms:  
1. Coagulative necrosis; 
2. Cavitation;  
3. Heat damage. 
These three key-points are discussed below. 
5.1 Coagulative necrosis 
Coagulative necrosis, is due to hyperthermia (85-100°C) generated in the focal point.  
Elementary lesion has ellipsoidal shape. The short length of the shot limits heat diffusion 
around the focal point. Shot by shot, it is possible to generate a plethora of elementary 
lesions until all prostate tissue is destroyed. 
Coagulative necrosis is a non-reversible phenomenon (Fig. 5). 
 
 
Fig. 5. On the left, pre-HIFU histology aspect; on the right, post-HIFU histology change 
This kind of lesion can be clearly seen on optical microscopy. Its effectiveness in cancer 
treatment is demonstrated by the absence of cell functional structures, such as membranes, 
active nuclei, and organelles.  
After the treatment, glandular structures cannot be seen any longer, thus demonstrating that 
the HIFU technique provides a lack of function in the treated prostate.  
Also liquefactive necrosis and apoptotic necrosis are reported as a common consequence of 
HIFU treatment (see § 6.1), but these kinds of necrotic lesions do not affect the whole 
amount of necrotic areas. 
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Cavitation is due to the gas microbubble (bubble clouds) vibration dissolved in prostate tissue. 
Lindau and Lauterborn investigated the collapse and rebound of a cavitation bubble near a flat 
rigid wall using a high-speed camera9.  
Due to the depression caused by the negative part of the ultrasound wave, intracellular water 
may enter the gaseous phase.  
That would lead to the development of microbubbles.  
When they reach the size of resonance, these bubbles suddenly collapse and produce high-
pressure shock waves, destroying adjacent tissue. 
In a study carried out by Chen H and colleagues10, the dynamics of cavitation bubble clouds 
generated at the tissue boundary in continuous HIFU fields has been experimentally 
investigated by a high-speed photography method.  
The experimental results revealed that the cavitation bubble clouds organize into two 
shapes, which were named ‘‘cone-shape” bubble cloud structure and ‘‘crown-shape” bubble 
cloud structure.  
The cavitation bubble cloud is visible at the tissue surface at 200 µs; then a tiny tip becomes 
obvious at 600 µs. The elongated tip leads to the formation of a cone-shape bubble cloud 
structure.  
After 1.8 ms, the cone-shape bubble cloud attaines a dynamically stable state.  
The bubble cluster grows larger and developes a crown-like shape. Meanwhile, it moves 
forward and finally hits the tissue boundary forming the crown-shape cavitation bubble 
cloud structure.  
Among the 171 image series recorded in the study carried out by Chen H et al, 85% showed 
the evolution of the cone-shape bubble cloud structure. Another 11% of the image series 
showed the dynamics of the crown-shape bubble cloud structure.  
The remaining 4% exhibited the interchanging of these two structures. 
5.3 Heat damage 
The tissue ablation induced by high-intensity ultrasound results primarily from bulk 
heating, with possible contributions from boiling and acoustic cavitation. Bubbles, when 
present, may enhance local absorption (Fig. 6).  
The position and shape of the heated region are determined by the intensity of the field near 
the focus, the attenuation and the effects of diffusion.  
The rate of change of temperature at any point is proportional to the absorbed power 
density and hence to the incident beam power and attenuation11.  
The irreversible changes in proteins associated with tissue denaturation and coagulation 
start at low temperature.  
When temperatures of approximately 60°C are approached, the rate of denaturation 
becomes so great that irreversible changes can occur in seconds.  
Temperature reached during HIFU treatment is clearly higher, as reported above: When 
lesioning occurs, the attenuation within the treated volume increases12, thus altering the 
absorbed power distribution, depending on the biologic feature of the prostate.  
Consequently, the region in which heat is deposited may be expected to change during the 
heating process. 
By a macroscopic point of view, we can say that heat growth is maximal in the middle of the 
treated volume and minimal in the external area of the treated volume.  
www.intechopen.com
High-Intensity Focused Ultrasound (HIFU) 
- An Alternative Choice in Prostate Cancer Treatment 
 
157 
This difference allows to surely set the treatment outlines and save the prostate apex, and 




Fig. 6. Elementary lesion formation and its effects on prostate parenchyma, due to heat and 
mechanical damage. 
6. HIFU-induced histopathological changes 
HIFU-induced histopathological changes can be studied thanks to light microscopy, 
immunoistochemistry and electron microscopy. 
6.1 Light microscopy 
At light microscopy, we can say that the prostatic structure is completely disrupted and 
hardly recognizable. Three different types of cellular necrosis are generally found: 
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a. liquefactive necrosis; 
b. coagulative necrosis; 
c. apoptotic necrosis.  
Cell death is generally due to a mixture of the three with liquefactive necrosis being the least 
common and coagulative necrosis the most common. 
Histological findings show consistent coagulative necrosis with precisely defined, sharp 
margins to normal tissue.  
Lesion size and position correlates well with the assumed target zones, thus demonstrating 
that HIFU permits therapeutic tissue ablation. 
Strictly speaking, HIFU treatment induces a spectrum of morphological changes ranging 
from apparent light microscopic necrosis to more subtle ultrastructural cell damage (see 
below). 
Necrotic tissue in the coagulative necrosis areas consists of homogenously stained 




Fig. 7a. Areas of coagulative necrosis can be clearly seen, thus demonstrating the 
effectiveness of HIFU treatment. 
Little structure is apparent aside from some faintly staining collagenous bands and rare 
indications of the former glandular epithelium. In some cases, necrotic tissue expelled from 
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the coagulative necrosis areas is visible in prostatic ductules of the margin area. Brightly 
staining blood droplets can be observed on the hematoxylin-eosin slide, of which most are 
concentrated in the coagulative necrosis area. 
The nuclei of epithelial and stromal cells are either pyknotic or totally absent, corresponding 
to cell necrosis. The nuclei are of normal size with a fine chromatin structure and 
sporadically small nucleoli. 
This epithelial cells also contain pale to eosinophilic cytoplasm, with few vacuoles. Although 
cell borders are not discernable in most of these cells, they can be identified locally. 
Every so often, extended haemorragic areas are found (Fig. 7b). 
 
 
Fig. 7b. Areas of tissue damage, including haemorragic areas 
Also, HIFU causes injuries to small vessels, with considerable oedema and swelling of 
endothelial cells in the margin between the treated and untreated areas. However, in the 
centre of treated tumor tissue, severely damaged tumor vessels show pyknotic nuclei and 
debris of nuclei, which indicated endothelial cell death. 
Endothelial cells exhibited an irreversible cell death. Almost all of the endothelial cell nuclei 
disappear, cellular margins were not distinct and junctions between individual cells were 
disrupted. 
The repair of lesions appears to have slow processes of damaged tissue absorption and 
granulation tissue replacement (Fig. 8). 
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Fig. 8. Granulation tissue and fibrosis 6 months after HIFU treatment. 
6.2 Immunoistochemistry 
The expression of PSA, panCK, and Ki67 in non-treated regions of the prostate is marginally 
stronger than in the HIFU region. CK8 is strongly expressed in luminal cells of normal and 
malignant glands outside the HIFU lesion, but pre-existing and malignant epithelium 
within the HIFU lesion does not express CK8, regardless of the histomorphological changes 
in conventional light microscopy.  
The hyperplastic epithelium at the periphery of the HIFU lesions reacts with the basal cell 
antibody 34βE12. 
In summary, we can say that prostate glandular epithelium after HIFU treatment  reacts 
with antibodies to pancytokeratin, prostate specific antigen (PSA), and Ki67, but does not 
express cytokeratin 8, which is indicative of severe cellular damage. 
6.3 Electron microscopy 
Ultrastructural examination after HIFU reveals disintegration of cellular membranes and 
cytoplasmic organelles consistent with cell necrosis. 
Electron microscopy is not routinely performed. When performed, it confirms 
submicroscopical cellular damage in the centre of the HIFU lesion.  
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Electron microscopy is capable to demonstrate cell necrosis also in areas that show no 
apparent morphological cell necrosis by conventional light microscopy.  
Treated areas lack nuclear membranes, but show a fine chromatin pattern that is clumped at 
the periphery of the nuclei, and conspicuous nucleoli.  
The cytoplasm contain some vacuoles, but organelle structures and cell membranes are not 
generally identified. 
7. Immunologic response after HIFU 
T-lymphocytes appear in granulation tissue along the ablation margin in all HIFU-treated 
neoplasms, with no infiltration in those showing typical signs of coagulation necrosis.  
The tumor-infiltrating lymphocytes are found mainly in granulation tissue along with 
immature fibroblasts, new capillaries, and other inflammatory cells.  
This observation suggest that their infiltration occurs after HIFU ablation and that these 
tumor-infiltrating lymphocytes are new lymphocytes moving into the ablated neoplasms 
from peripheral blood.  
As it has been reported by Hartveit and colleagues, this is a typical findings in all tissues 
treated with HIFU13.  
HIFU treatment may definitively increase the local infiltration of tumor infiltrating 
lymphocytes in the ablation area, including activated cytotoxic T-Cells and Natural-Killer 
cells14.  
8. The role of heat-shock proteins (HSP) 
Heat shock proteins (HSPs) were first discovered in 1962 as a group of highly conserved 
proteins that are induced by hyperthermia and other kinds of cellular insults.  
There are four principal HSP: HSP-90, HSP-70, HSP-60 and the subgroup of small HSPs 
including HSP27.  
Benign and malignant human prostatic cells respond to heat by increased expression of HSP 
in vitro and in vivo. 
To obtain a more detailed insight on the effect of heat on prostatic cells, heat shock protein 
expression of normal and malignant prostatic cells has been studied. 
Transrectal HIFU therapy induces intraprostatic necrosis surrounded by a zone 
characterized by a massive up-regulation of HSP expression.  
Recently, several molecular heat shock proteins have been reported to be involved in 
development and progression of hormone-refractory prostate cancer. 
HSP27 and HSP70 are the most strongly induced heat shock proteins during cellular 
stress (Fig. 9). 
HSPs are not all of prognostic value, however some have been demonstrated to have clinical 
utility as prognostic markers: among this group of heat shock proteins, the most important 
one is HSP-27, which particularly plays a role in many immunological processes and might 
stimulate immune defence responses against tumour cells15. 
Accumulating evidence suggests that HSP27 levels correlate with both hormone-refractory 
prostate cancer and development of resistance to heat. Nevertheless, the functional 
significance of changes in HSP27 expression associated with heat-resistant  prostate cancer 
remains undefined. 
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Fig. 9. HSP-70 expression in prostate tissue after HIFU treatment in a case of recurrence 
9. Long-term results of HIFU treatment 
Many authors have reported their series after HIFU treatment. 
One of the most recent is the multicentric study carried out by Crouzet et al16, who reported 
a series of 803 patients with a mean follow-up of 43 months. The results of this study are 
excellent, showing that local control and disease-free survival rate achieved with HIFU were 
similar to those expected with conformal external-beam radiation therapy (EBRT). 
The excellent cancer-specific survival rate reported in this study is also explained by the 
possibility to repeat HIFU and use salvage EBRT. 
The first UK series was reported by Ahmed et al and published on the British Journal of 
Cancer. 172 men were treated with HIFU with excellent result: 92.4% of patients had no 
recurrence after a mean follow-up of 346 days17. 
Blana et al published a series of 140 men treated with HIFU, reporting good oncological 
outcome in long-term follow-up (6.4 years), demonstrating the effective long-term cancer 
control achieved with HIFU in patients with low- or intermediate-risk localised prostate 
cancer18. 
Finally, it is correct to cite the negative results reported by Challacombe et al, who 
interrupted the treatment because of the poor oncological outcome19. 
From all the studies presented, there is clear evidence that the treatment could affect 
prostate cancer, as shown by both a substantial decrease in serum PSA and negative 
biopsies after therapy there is clear evidence that the treatment could affect prostate cancer.  
The effect has also been demonstrated on radical prostatectomy specimens examined 2 
weeks after HIFU. 
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There are no randomized controlled studies available to compare the outcome of these 
therapies with each other, other therapies, or watchful waiting. 
The combination of a TURP performed just before an HIFU seems to reduce the 
complications but without affecting the oncologic outcome negatively. 
As of today, it is not possible to compare the outcome of HIFU with other treatment 
modalities for localized prostate cancer. 
10. Complications and side effects of HIFU treatment 
HIFU is a minimally invasive treatment for prostate cancer, thus resulting in a low 
complication rate.  
Sometimes, minor complications can occour, in the vast majority of cases related to lower 
urinary tract.  
The first one is urinary retention, commonly treated with longer catheterism. The most 
common is urge incontinence, due to the irritative effect of high-focused ultrasound on the 
bladder neck. Generally, it disappears in a couple of month, and only in rare cases 
anticolinergic treatment is required. 
Lower urinary tract symptoms, such as frequency, nocturia, weak urinary stream, and so on, 
are prevented by Trans-Urethral Resection of Prostate (TUR-P), that is recommended to be 
done 6-8 weeks before HIFU treatment. Anyway, the surgeon is advised to administrate 
IPSS questionnaire (or equivalent) before the treatment end 3 months after the treatment, in 
order to assess persistent lower urinary tract symptoms, that should be treated 
pharmacologically or surgically, if needed. 
Infection is another possible complication of this treatment. Antibiotic prophylaxis should 
prevent this complication, if administrated in accordance with guidelines on infection 
prevention. 
Among the major complications, the most important is recto-vesical or recto-urethral 
fistula. Only few cases are reported in literature. This complication can be initially treated 
with longer catheterization, but in some cases surgical repair is required. A common tip to 
avoid this complication is to safely set the target area on the ultrasound screen, as the 
slight wall of the rectum can easily lead to fistulization. Also, patients previously 
diagnosed with ulcerative recto-colitis must not be treated with high-intensity focused 
ultrasound. 
The most important side-effect of HIFU treatment is erectile disfunction and impotency, due 
to the effect of high intensity ultrasound on the neural bundle. This effect is well known and 
must be discussed with the patient before the treatment. 
Color-doppler-combined technique is reported in literature in order to perform a sort of 
vessel-sparing procedure, thus resulting in a better outcome by the andrological point of 
view. However, there is not common agreement among the investigators about the 
effectiveness and the feasibility of this technique. For this reason, it cannot be recommended 
at the present time (Fig. 10). 
The best management of the patient should include IIEF questionnaire (or equivalent) to be 
giver before the treatment and 6 months after the treatment in order to assess the sexual 
outcome. 
Patients who are keen on having sexual activity should receive a proper treatment. 
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not affected by tumor (red line). 
Fig. 10. Color-doppler device for HIFU treatment. Thanks to this additional equipment, it is 
possible to perform a highly selective treatment (blu line). This can preserve vascular bundle 
or a portion of prostate  
11. Summary 
At the time of diagnosis, prostate cancer is organ-confined in 70% of the cases.  
The choice of the appropriate treatment for localized prostate cancer is one of the most 
controversial issues in urologic oncology. Approximately, the most majority of these 
patients undergo local therapy: surgery or external beam radiation. The rest of the 
remaining patients do not fit this treatment and are scheduled for Androgen Depriving 
Therapy (ADT) or watchful waiting.  
Besides these treatments, other mini-invasive procedures have emerged in the last few 
years, such as Brachytherapy, Cryosurgical Ablation, Radiofrequency Interstitial Tumour 
Ablation and High-Intensity Focused Ultrasound (HIFU). 
HIFU represents an alternative choice in mini-invasive treatment of prostate cancer. The 
treatment is performed under regional anaesthesia and is generally preceeded by limited 
Trans-Urethral Resection of Prostate (TUR-P).  
It is a transrectal procedure: after introducing the rectal probe, anatomic limits must be 
echographically set (apex, bladder neck, rectal side, prostate capsule), in order to make the 
computer able to determine the correct subdivision in different prostate portions (generally four).  
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An absolute contraindication to the procedure is every rectal anatomic or pathologic 
condition that excludes the transrectal approach. 
The technology of the device used to perform the treatment allows to exactly destroy a pre-
selected area and to save all the tissues around it. 
Conceptually, a piezoelectric trasducer generates a high intensity converging ultrasound 
beam that destroys local tissues through three mechanisms:  
1. coagulative necrosis, due to hyperthermia (85-100°C) generated in the focal point. 
Elementary lesion is ellipsoidal and the short length of the shot limits heat diffusion 
around the focal point. Shot by shot, it is possible to generate a plethora of elementary 
lesions until all prostate tissue is destroyed;  
2. cavitation, due to the gas microbubble vibration dissolved in prostate tissue;  
3. heat growth, maximal in the middle of the treated volume and minimal in the external 
area of the treated volume.  
This difference allows to surely set the treatment outlines and save the prostate apex (and 
the striated sphincter) and vasculo-nervous bundles.  
HIFU is a minimally invasive ablative technology for managing localized prostate cancer in 
both the primary and salvage setting. It is a single-session procedure with the possibility of 
a re-treatment if required.  
The advantage of this technique are short hospital stay, reduced convalescence, low 
morbidity and preservation of continence and erectile function. 
As reported in literature, HIFU demonstrated a good oncologic outcome.  
The PSA nadir is a major predictive factor for HUFU success and it is generally reached 
within 6 months after the treatment in all patients.  
The most recent results are reported in a study carried out by Crouzet et al. In this 
multicentric study  the mean PSA nadir was 1.0±2.8 ng/mL with a median of 0.25 ng/mL. 
The 5-year and 7-year Disease Free Survival Rate (DFSR) for low, intermediate-, and high-
risk patients (according to D’Amico risk stratification criteria) were, respectively, 83-75%, 
72-63% and 68-62%. 
As expected by most investigators, the development of more sophisticated technologies 
should improve these results and lead to a widespread use of this technique. Focal 
treatment or doppler-combined devices for nerve- or vessel- sparing procedures will be 
available in the next years. 
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